HuGEMM™ PD-1 Mouse Model

FATZO Mouse

cvmd-magnifyglass.png

HuGEMM™ PD-1 Mouse Model Description

The HuGEMM PD-1 mouse model is a chimeric tumor model where the mouse immune system is functional and the PD-1 receptors have been humanized for a more translational immune response.

The PD-1 model  was developed by knocking-in human exon 2 to replace its mouse counterpart, which allows the receptor to be recognized by therapeutic antibodies of interest. This enables the ability to test the therapeutic efficacy directly in the mouse model.

PD-1 plays an important role in the immune response, down-regulating the immune system and suppressing T cell inflammatory activity.

Benefits of HuGEMM Models

  • Humanized drug targets eliminate and reduce interspecific (species) effects of the compound providing a platform to evaluate therapeutic antibodies which are not cross-reactive to the mouse protein

  • Enables the evaluation of specific human biological therapies in vivo when no mouse ortholog is available

  • Provides an efficient method to study a range of targets for human immunotherapies

PD-1 Model Characterization Data

Figure 1 (data generated by Nanjing Galaxy Biopharmaceutical Co. Ltd): The chimeric h/mPD-1 protein binds in vitro to both mouse and human PD-L1 as efficiently as the human PD-1 receptor (upper panel). The chimeric protein is also recognized by anti-human PD-1 antibodies (lower panel), which disrupts the PD-1/PD-L1 interaction

Figure 2: Validation of HuGEMM PD-1 with an analog of Opdivo®. Dose dependent inhibition of subcutaneous MC38 tumor growth is observed following treatment with the anti-hPD-1 antibody.